Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 6 recruiting now full pipeline small index

Lung Diseases, Interstitial: full-pipeline trial registry

6 of 11 indexed Lung Diseases, Interstitial trials are currently recruiting.

Corpus placement: #1,577 of 28,707 conditions by registered trial count.

11 US clinical trials · 6 currently recruiting · #1,577 of 28,707 conditions by registered trial count

Lung Diseases, Interstitial: 11 US clinical trials tracked, 6 recruiting.

Lung Diseases, Interstitial is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Boehringer Ingelheim, running 2 of these trials.

Enrollment posture brief

Registry condition lung-diseases-interstitial

OPEN 6 | RECR 55% | LATE 2 | EARLY 2 | RANK #1577 | SPON 2

Nearest open-share peer: Advanced Ovarian Carcinoma (55% recruiting · 11 trials)

Acute Pancreatitis81.8%Lung Diseases, Interstit (th…55%Acute Stroke45.5%Acquired Brain Injury36.4%Acute Lung Injury9.1%
Open-enrollment share among volume-matched conditions near Lung Diseases, Interstitial

Lung Diseases, Interstitial lists 6 open slots (55% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Lung Diseases, Interstitial on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Lung Diseases, Interstitial is recruiting above its size-band peers.

    6 of 11 indexed trials (54.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Lung Diseases, Interstitial research.

    Boehringer Ingelheim accounts for 2 of 11 trials (18.2%). 10 distinct sponsors appear on at least one study for this condition label.

  3. Typical Lung Diseases, Interstitial enrolment sits around 70 participants.

    Median target enrolment is 70 among the 11 trials that report a genuine target (sentinel values excluded). 6 of those (54.5%) plan for fewer than 100 participants.

  4. Lung Diseases, Interstitial research is mostly interventional.

    8 interventional and 3 observational studies make up this index (72.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 21Phase 32

Open and recent trials

11 total, page 1 of 1

RECRUITING 5,000 participants

Dorothy P. and Richard P. Simmons Center for ILD Research Registry

University of Pittsburgh

NCT00258583

RECRUITING 2,000 participants

Cough Capture as a Portal Into the Lung

Albert Einstein College of Medicine

NCT05854563

RECRUITING Phase 3 440 participants

A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

GlaxoSmithKline

NCT06572384

RECRUITING NA 70 participants

Physical Activity and Quality of Life in Fibrotic Lung Diseases After Initiating Anti-fibrotic Therapy and Pulmonary Rehabilitation

University of South Florida

NCT05866198

RECRUITING Phase 1 50 participants

Nebulized Human Amniotic Fluid in Patients With Interstitial Lung Disease

Maule Stem Cell Research Institute

NCT07372989

RECRUITING Phase 2 37 participants

H01 in Adults With Interstitial Lung Disease (The SOLIS Study)

National Institute of Environmental Health Sciences (NIEHS)

NCT06325696

ACTIVE NOT RECRUITING NA 5 participants

Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD

Third Pole Therapeutics

NCT05867914

COMPLETED 114,921 participants

Oxygen Therapy Use in Patients With Fibrotic Interstitial Lung Disease

Boehringer Ingelheim

NCT05957198

COMPLETED NA 2,512 participants

Project to Improve Communication About Serious Illness--Hospital Study: Pragmatic Trial (Trial 1)

University of Washington

NCT04281784

COMPLETED Phase 3 39 participants

A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)

Boehringer Ingelheim

NCT04093024

COMPLETED NA 11 participants

Oxygen Savings With Administered Oxygen and High Flow Ambient Air At Rest

Johns Hopkins University

NCT04170062

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1
Phase 3 2

Named interventions

Most-linked intervention names on Lung Diseases, Interstitial records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

EHR-based Clinician Jumpstart Behavioral
1 trials
Nasal Delivery of Oxygen Therapy Device
1 trials
Nasal Delivery of High-Flow Air and Oxygen Therapy Device
1 trials
Inhaled Nitric Oxide (iNO) Device
1 trials
Nintedanib Drug
1 trials
Observational only, all subjects; measure DNA mutation and proteomic survey. Other
1 trials
Actigraph CP Insight Watch Diagnostic test
1 trials
Matrix Biological
1 trials

US sites by state

Facility locations filed on Lung Diseases, Interstitial trials. A trial with sites in several states counts in each.

Florida 4 trials
Pennsylvania 3 trials
New York 3 trials
Washington 2 trials
North Carolina 2 trials
Missouri 2 trials
California 2 trials
Utah 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Lung Diseases, Interstitial page

11 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 6 Lung Diseases, Interstitial trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Boehringer Ingelheim sponsors the most Lung Diseases, Interstitial trials on record, review their full trial history before evaluating a specific study. See Boehringer Ingelheim's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lung Diseases, Interstitial condition card totals 11 registered trials; most-linked intervention EHR-based Clinician Jumpstart; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.